Huadong Medicine (SHE:000963) won pre-bids for three of its products under China's drug procurement program, according to a Monday disclosure to the Shanghai bourse.
The pre-selected drugs include the cyclosporine soft capsules and tacrolimus capsules for immunology, as well as mesalazine enteric-coated tablets for inflammatory bowel diseases.
Total sales of its winning products reached 2.08 billion yuan in 2025.
Shares fell 2% during the midday break on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments